News | December 07, 2025
Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Angelini Ventures has already invested €125 million in 22 startups
Subscribe To Our Newsletter & Stay Updated
